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Antibody acquisition models: A new 
tool for serological surveillance of 
malaria transmission intensity
Victor Yman1, Michael T. White2, Josea Rono1,3, Bruno Arcà4, Faith H. Osier3, Marita Troye-
Blomberg5, Stéphanie Boström5, Raffaele Ronca6, Ingegerd Rooth7 & Anna Färnert1
Serology has become an increasingly important tool for the surveillance of a wide range of infectious 
diseases. It has been particularly useful to monitor malaria transmission in elimination settings 
where existing metrics such as parasite prevalence and incidence of clinical cases are less sensitive. 
Seroconversion rates, based on antibody prevalence to Plasmodium falciparum asexual blood-stage 
antigens, provide estimates of transmission intensity that correlate with entomological inoculation 
rates but lack precision in settings where seroprevalence is still high. Here we present a new and widely 
applicable method, based on cross-sectional data on individual antibody levels. We evaluate its use as a 
sero-surveillance tool in a Tanzanian setting with declining malaria prevalence. We find that the newly 
developed mathematical models produce more precise estimates of transmission patterns, are robust in 
high transmission settings and when sample sizes are small, and provide a powerful tool for serological 
evaluation of malaria transmission intensity.
In order to reduce the global malaria burden and achieve control, or even elimination, robust estimates of malaria 
transmission intensity are required for the strategic planning, implementation and evaluation of interventions1–4. 
Efficient monitoring of malaria transmission intensity depends on tools that produce reliable estimates across a 
wide range of transmission settings5,6. Such tools should preferably integrate information about both parasite and 
vector populations to capture the current level of transmission intensity as well as the transmission potential in 
areas where parasite carriage has decreased but vector populations persist6–9.
Traditionally, transmission intensity has been estimated by a variety of techniques such as spleen rates, par-
asite prevalence or entomological inoculation rates (EIR)2. EIR has been considered the gold standard among 
metrics10, but is expensive and labour intensive to evaluate and estimates are often imprecise (especially when 
transmission is low) due to marked heterogeneity of both malaria transmission and vector distribution10–12. In 
addition, single-time point evaluation of parasite prevalence or EIR provides limited information about past 
transmission intensity13,14. Cumulative exposure to P. falciparum, however, can be estimated by evaluation of 
antibody responses to P. falciparum blood-stage antigens15–17. In addition, exposure to Anopheles mosquitoes can 
be evaluated through antibody responses to An. gambiae salivary gland protein 6 (gSG6)18–20.
Existing methods for serological evaluation of malaria transmission have largely been based on cross-sectional 
data on antibody prevalence and on estimation of seroconversion rates (SCR) using serocatalytic models as shown 
by Drakeley et al.15. Although SCR based estimates have been extended to evaluate temporal changes21–23 and 
provide robust information about medium and long-term trends of transmission intensity, they are insensitive 
to changes in high transmission settings and to smaller and more short-term trends due to the quick acquisition 
of antibody responses and the long half-life of seropositivity to many blood-stage antigens15,24,25. The sensitivity 
and precision can be improved by selecting antigens that are less immunogenic or to which seropositivity is more 
short-lived15,26 and, as duration of seropositivity appears to be age-dependent27, by focusing analysis on antibody 
responses among children only and by using data from multiple cross-sectional surveys28. Nonetheless, recent 
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changes in exposure, and changes occurring in high exposure settings, are better reflected by population antibody 
levels29–31. SCR based estimates could potentially be further improved by the application of a model that makes 
use of the data on individual antibody levels by assuming that antibody levels increase as a function of age, and 
that the rate at which they are boosted by exposure can be used as a marker of transmission intensity.
Here we aim to improve serological estimates of malaria transmission intensity by developing new mod-
els based on cross-sectional data on individual antibody levels. We evaluate transmission changes in a rural 
Tanzanian village that has experienced a gradual decline of P. falciparum prevalence from 1985 to 2010, but where 
lack of surveillance between 2000 and 2009 hinders efforts to fully elucidate patterns of malaria transmission 
intensity32 (Fig. 1). To maximise the sensitivity to detect transmission changes, we included children 1–16 years 
old participating in cross-sectional surveys conducted in 1999 (n = 313) and 2010 (n = 355) and measured anti-
body responses to recombinant P. falciparum antigens (MSP-1, MSP-2, MSP-3, AMA-1) and gSG6. P. falciparum 
antigens were selected based on previous evaluation with serocatalytic models15,20,27. We compare the perfor-
mance of the newly developed models, referred to as antibody acquisition models, to previously validated sero-
catalytic models. We show that the antibody acquisition models increase precision in transmission estimates and 
provide a powerful and widely applicable new tool for serological surveillance of malaria transmission dynamics.
Results
The prevalence of P. falciparum infection in children age 1–16 was 77.1% (95% CI: 71.2, 81.8) in 1999 and 23.7% 
(95% CI: 15.7, 24.3) in 2010 when evaluated by real-time PCR32. We defined the threshold for seropositivity 
as the mean reactivity, plus three standard deviations, of sera from unexposed Swedish donors (see Methods). 
In addition, we evaluated an alternative threshold for seropositivity defined using finite mixture models (see 
Methods). Results from serocatalytic models fitted to seroprevalence data based on the alternative threshold are 
presented in full as supplementary information. For all antigens, both prevalence (χ 2-test: all P < 0.001) and lev-
els (Mann-Whitney-U-test: all P < 0.001) of antibodies were higher in 1999 than 2010. Seroprevalence and levels 
of antibodies to P. falciparum antigens increased with age at both surveys, except for MSP-119, MSP-3_3D7 and 
MSP-3_k1 in the 2010 cross-section where levels were similar across age groups. Seroprevalence and antibody 
levels to gSG6 did not show discernible age trends at either survey. Data on antibody levels were approximately 
log-normally distributed for all antigens (see Supplementary Fig. S3 online) and highly correlated between the 
two allelic variants of AMA-1 and MSP-3, while less correlated for MSP-2 (see Supplementary Fig. S4 online).
Modelling serological data. Based on our previous knowledge of the gradual reduction in parasite preva-
lence in Nyamisati32 (Fig. 1), we considered three functional forms for the changing pattern of malaria transmis-
sion over time: (i) constant transmission; (ii) a sharp stepwise reduction; (iii) a linear decline. The serocatalytic 
models and the new antibody acquisition models were fitted to the data for each antigen and transmission profile 
using maximum-likelihood estimation (see Methods). For each individual antigen and transmission pattern, 
models were fitted simultaneously to data from the two cross-sectional surveys.
Serocatalytic models. In Fig. 2 we present age-seroprevalence plots and the three models fitted for each of the 
antigens at both cross-sections. Estimates of SCR (λ) and seroreversion rates (ρ) for each model and antigen are 
presented in Table 1 together with the estimated time (tc) and magnitude of reduction (γ). As expected, model 
1 provided poor fit to data for all antigens and a visual assessment of the fitted models in the age-seroprevalence 
plots indicated that model 1 underestimated the proportion of seropositives in 1999 while simultaneously over-
estimating the proportion of seropositives in 2010 (Fig. 2). The stepwise decrease model (model 2) estimated an 
approximate 44–79% reduction of SCR for P. falciparum antigens from 1983–2010 (Table 1). The reduction was 
estimated to have occurred between 1997 and 2007, with most point estimates clustered between 1997 and 2000 
(Table 1,  Fig. 3a). AMA-1_3D7, AMA-1_FVO and MSP-3_K1 provided precise estimates of “time of change” (tc) 
whereas estimates from MSP-119, MSP-2_Dd2, MSP-2_CH150/9 and MSP-3_3D7 and gSG6 showed substantial 
uncertainty (Table 1). Model 3 estimated high initial SCRs in 1983 and large reductions for all antigens between 
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Figure 1. All age parasite prevalence in Nyamisati 1985–2010 by microscopy and species specific real-time 
PCR32. (*) Microscopy prevalence in 2010 was estimated from PCR data using the prevalence estimation tool 
developed by Okell et al. Nat Commun. 2012. Arrows indicate the time-points for distribution of insecticide 
treated nets (ITNs) and long-lasting insecticidal nets (LLINs).
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1983 and 2010. The estimated reduction ranged from 65–96% for the P. falciparum antigens (Table 1, Fig. 3a). 
Model comparison using the Akaike Information Criterion (AIC) revealed that models 2 and 3, which capture 
reductions in transmission, provide considerably better fits to the data than model 1 (Table 1). According to 
Figure 2. Best-fit serocatalytic models. Black points denote the proportion of seropositive individuals and 
vertical bars denote 95% confidence intervals. Model 1: stable transmission (solid lines). Model 2: stepwise 
reduction in transmission (dotted lines). Model 3: linear reduction in transmission (dashed lines).
Antigen Model λ0 γ ρ tc
Log- 
likelihood AIC
AMA-1_3D7
M1 0.17 (0.16, 0.22) – 0.0 (0.0, 0.02) – − 65.74 135.48
M2 0.32 (0.26, 0.44) 0.35 (0.26, 0.46) 0.003 (0.0, 0.015) 1999 (1997, 2001) − 31.59 71.19
M3 0.51 (0.39, 0.69) 0.11 (0.04, 0.21) 0.004 (0.0, 0.016) – − 34.92 75.85
AMA-1_FVO
M1 0.20 (0.18, 0.24) – 0.0 (0.0, 0.01) – − 60.30 124.60
M2 0.34 (0.29, 0.43) 0.39 (0.29, 0.52) 0.003 (0.0, 0.013) 1999 (1997, 2001) − 33.48 74.96
M3 0.53 (0.41, 0.74) 0.14 (0.06, 0.27) 0.004 (0.0, 0.015) – − 36.11 78.23
MSP-119
M1 0.25 (0.19, 0.34) – 0.045 (0.02, 0.08) – − 42.20 88.41
M2 0.36 (0.26, 0.56) 0.33 (0.26, 0.73) 0.06 (0.03, 0.10) 2007 (1997, 2009) − 35.53 79.07
M3 0.50 (0.31, 0.91) 0.35 (0.17, 0.66) 0.05 (0.03, 0.09) – − 36.88 79.77
MSP-2_Dd2
M1 0.19 (0.17, 0.22) – 0.0 (0.0, 0.01) – − 38.87 81.75
M2 0.26 (0.21, 0.41) 0.56 (0.31, 0.75) 0.0 (0.0, 0.01) 1997 (1994, 2006) − 29.60 67.20
M3 0.35 (0.26, 0.51) 0.34 (0.18, 0.57) 0.002 (0.0, 0.016) − 29.81 65.62
MSP-2_CH150/9
M1 0.24 (0.21, 0.31) – 0.007 (0.0, 0.02) – − 48.32 100.65
M2 0.43 (0.29, 0.64) 0.28 (0.14, 0.60) 0.016 (0.0, 0.03) 2004 (1997, 2006) − 31.52 71.04
M3 0.64 (0.44, 1.06) 0.17 (0.07, 0.34) 0.011 (0.0, 0.027) – − 31.74 69.49
MSP-3_3D7
M1 0.26 (0.18, 0.45) – 0.14 (0.08, 0.28) – − 85.19 174.39
M2 0.62 (0.31, 2.69) 0.24 (0.04, 0.34) 0.16 (0.06, 0.61) 1999 (1996, 2008) − 43.31 94.62
M3 2.15 (1.06, 8.44) 0.05 (0.01, 0.11) 0.26 (0.15, 0.70) – − 44.24 94.48
MSP-3_K1
M1 0.07 (0.06, 0.12) – 0.02 (0.0, 0.09) – − 94.18 192.37
M2 0.16 (0.11, 0.26) 0.21 (0.14, 0.29) 0.03 (0.0, 0.06) 1998 (1996, 1999) − 51.26 86.50
M3 0.25 (0.16, 0.41) 0.04 (0.0, 0.11) 0.04 (0.01, 0.09) – − 48.16 102.32
gSG6
M1 0.14 (0.06, 4.18) – 0.32 (0.12, 10.0) – − 56.82 117.64
M2 0.24 (0.11, 3.52) 0.22 (0.01, 0.46) 0.34 (0.15, 1.68) 2006 (1996, 2009) − 37.68 83.36
M3 0.47 (0.21, 4.33) 0.11 (0.04, 0.23) 0.35 (0.17, 4.10) – −38.03 82.07
Table 1. Serocatalytic model parameter estimates. Maximum likelihood parameter estimates and 95% 
confidence intervals for serocatalytic models fitted to cross-sectional age-specific seropositivity data. λ0 is the 
seroconversion rate, γ (= λc/λ0) is the reduction in transmission, ρ is the seroreversion rate, tc is the estimated 
time-point (calendar-year) of drop in transmission, log-likelihood is the maximised log-likelihood of the model 
and AIC is the Akaike Information Criterion value. A bold font indicates the smallest AIC for each of the 
antigens. Confidence Intervals were defined using profile-likelihood methods.
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the classification suggested by Burnham and Anderson33 (∆AIC < 2: substantial support for alternative models; 
∆AIC = 4–7: considerably less support; ∆AIC > 10: no support), there was sufficient information only to deter-
mine that model 2 was the superior model for AMA-1 and MSP-3_k1 whereas for the other antigens, AIC-values 
were similar between models 2 and 3 (Table 1). Serocatalytic models fitted to seroprevalence data based on the 
alternative threshold for seropositivity estimated lower SCR and higher seroreversion rates, but results were in all 
other aspects similar and the alternative choice of threshold did not affect model performance (see Supplementary 
Fig. S5 and Supplementary Table S1 online).
Antibody acquisition models. Antibody acquisition models were designed to capture the rate of increase in anti-
body levels with age and provide an alternative measure of transmission intensity. Age group-specific geometric 
mean antibody levels and the antibody acquisition models fitted to data for each of the antigens are presented in 
Fig. 4. Maximum likelihood parameter estimates of antibody acquisition (a) and decay rates (r), timing (tc) and 
magnitude of reduction (γ) are shown in Table 2. Model 2 (i.e. stepwise decrease model) provided superior fit to 
data (with the lowest AIC values) compared to both model 3 and model 1 for all P. falciparum antigens (Table 2). 
Model 2 estimated reductions of antibody acquisition rates for P. falciparum antigens ranging from 72–92% 
between 1983 and 2010 (Table 2, Fig. 3b) with a stepwise reduction estimated to have occurred between 1997 and 
1999 for antigens AMA-1_FVO, AMA-1_3D7, MSP-2_Dd2, MSP-2_CH150/9 and MSP-3_K1 (Table 2, Fig. 3b). 
MSP-119 and MSP-3_3D7, showing no age-trend in antibody levels at the second cross-section, as well as gSG6, 
with no age-trend at either cross-section, each provided estimates with considerable uncertainty (Table 2, Fig. 3b). 
Model 3 estimated reductions of antibody acquisition rates from 41–100%, approaching 100% for several of the P. 
falciparum antigens (AMA-1_3D7, AMA-1_FVO, MSP-119, MSP-2_Dd2, and MSP-2_CH150/9), indicating zero 
transmission in 2010 and thus a poor choice of pattern of transmission intensity (Table 2, Fig. 3b).
Model comparison: Antibody acquisition models versus serocatalytic models. The serocata-
lytic models use continuous antibody data that has been dichotomised while the antibody acquisition models 
use data on the actual individual antibody level and age. The different types of data restrict a formal statistical 
comparison; however, the performance of the models can be evaluated and compared using profile likelihood 
plots (see Supplementary Information online). The antibody acquisition models generally provided a better and 
more consistent fit to data than the serocatalytic models. The difference is evident from the profile likelihood 
plots, in particular for the parameter “time of change” (tc) for serocatalytic and antibody acquisition model 2 (see 
Supplementary Fig. S1 and S2 online). Although the point estimates of parameter tc were overall similar for both 
serocatalytic and antibody acquisition models, the larger amount of data utilised by the antibody acquisition 
models gave better fit and provided higher precision of the estimates as indicated by the much more narrow con-
fidence intervals (Table 1 and 2).
a
b
Figure 3. (a) Estimated changes in historical transmission from serocatalytic models (model 2 and model 3). 
(b) Estimated changes in historical transmission from antibody acquisition models (model 2 and model 3).
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We performed a complementary sensitivity analysis (see Supplementary Figs S6 and S7 online), using both 
simulated data and the data for AMA-1_FVO, to evaluate the robustness of serocatalytic and antibody acquisition 
model 2 to reductions in the sample size. Reductions in sample size (e.g. to 100 or 50 samples per cross-section) 
Figure 4. Best-fit antibody acquisition models. Black points denote geometric mean antibody levels in 
arbitrary units (AU) and vertical bars denote the 95% range of the data. Model 1: stable transmission (solid 
lines). Model 2: stepwise reduction in transmission (dotted lines). Model 3: linear reduction in transmission 
(dashed lines).
Antigen Model α0 γ r tc σ Log-likelihood AIC
AMA-1_3D7
M1 0.27 (0.24, 0.34) – 0.0 (0.0, 0.03) – 2.18 (2.06, 2.29) − 2026.17 4058.35
M2 0.89 (0.66, 1.32) 0.09 (0.07, 0.14) 0.0 (0.0, 0.05) 1998 (1997, 1999) 1.92 (1.82, 2.02) − 1942.73 3895.45
M3 1.55 (0.91, 2.72) 0.009(0.001,0.04) 0.10 (0.01, 0.20) – 1.97 (1.88, 2.08) − 1961.93 3931.85
AMA-1_FVO
M1 0.28 (0.24, 0.34) – 0.0 (0.0, 0.02) – 2.23 (2.11, 2.35) − 2052.93 4111.85
M2 0.95 (0.66, 1.47) 0.08 (0.06, 0.12) 0.0 (0.0, 0.06) 1998 (1997, 2000) 1.93 (1.81, 2.06) − 1957.98 3925.96
M3 1.48 (0.72, 2.53) 0.003(0.001,0.03) 0.08 (0.0, 0.18) – 2.00 (1.91, 2.11) − 1980.09 3968.18
MSP-119
M1 0.47 (0.34, 0.71) – 0.07 (0.0, 0.18) – 1.67 (1.59, 1.77) − 1998.72 4003.44
M2 7.8. (1.2, 45.5) 0.084 (0.016, 0.28) 0.23 (0.02, 0.45) 1991 (1988, 2002) 1.64 (1.55, 1.72) − 1987.69 3985.38
M3 1.19 (0.71, 2.01) 0.29 (0.17, 0.49) 0.13 (0.05, 0.25) – 1.65 (1.57, 1.74) − 1988.70 3985.40
MSP-2_Dd2
M1 0.50 (0.44, 0.59) – 0.0 (0.0, 0.02) – 2.03 (1.92, 2.14) − 2381.28 4768.56
M2 1.96 (1.56, 2.92) 0.08 (0.06, 0.11) 0.0 (0.0, 0.05) 1997 (1996, 1998) 1.70 (1.61, 1.81) − 2263.92 4537.84
M3 3.37 (2.02, 5.58) 0.002 (0.001,0.2) 0.12 (0.04, 0.22) – 1.79 (1.69, 1.88) − 2296.06 4600.12
MSP-2_CH150/9
M1 0.58 (0.49, 0.71) – 0.0 (0.0, 0.02) – 2.26 (2.14, 2.39) − 2562.06 5130.12
M2 1.95 (1.52, 3.28) 0.08 (0.06, 0.11) 0.0 (0.0, 0.06) 1998 (1997, 1999) 1.95 (1.84, 2.06) − 2463.86 4937.71
M3 3.64 (2.13, 6.37) 0.0 (0.0, 0.02) 0.11 (0.02, 0.21) – 2.01 (1.91, 2.11) − 2483.66 4975.31
MSP-3_3D7
M1 6.80 (4.53, 12.97) – 0.34 (0.19, 0.72) – 1.17 (1.12, 1.24) − 2976.95 5959.90
M2 29.98 (3.0,100) 0.08 (0.07,0.15) 0.35 (0.31,0.48) 1992 (1990, 1993) 1.15 (1.10,1.22) − 2966.78 5943.55
M3 10.59 (6.18, 22.8) 0.59 (0.42, 0.86) 0.38 (0.22, 0.79) – 1.16 (1.10, 1.24) − 2973.43 5954.87
MSP-3_K1
M1 1.20 (0.84, 1.89) – 0.06 (0.0, 0.17) – 1.81 (1.71, 1.90) − 2706.36 5418.72
M2 2.90 (1.87, 6.69) 0.28 (0.18, 0.39) 0.10 (0.03, 0.22) 1998 (1996, 2001) 1.73 (1.63, 1.82) − 2675.38 5360.75
M3 4.99 (3.07, 9.0) 0.14 (0.07, 0.23) 0.17 (0.09, 0.33) – 1.74 (1.65, 1.84) − 2680.85 5369.70
gSG6
M1 18.2 (12.7, 32.1) – 0.82 (0.55, 1.50) – 0.69 (0.65, 0.73) − 2677.39 5360.78
M2 27.6 (17.1, 39.4) 0.64 (0.42,0.75) 1.02 (0.60,1.50) 2008 (1997, 2009) 0.66 (0.63,0.71) − 2651.88 5313.75
M3 37.25 (23.9, 42.5) 0.46 (0.38, 0.55) 0.96 (0.65, 1.19) – 0.66 (0.63, 0.71) − 2652.21 5312.41
Table 2. Antibody acquisition model parameter estimates. Maximum likelihood parameter estimates and 
95% confidence intervals for antibody acquisition models fitted to cross-sectional antibody levels data. α0 is the 
rate of antibody boosting, γ (= αc/α0) is the reduction in transmission, r is the rate of antibody decay, tc is the 
estimated time-point (calendar year) of drop in transmission, σ is the standard deviation of the antibody levels 
on the log scale, log-likelihood is the maximised log-likelihood of the model and AIC is the Akaike Information 
Criterion value. A bold font indicates the smallest AIC for each of the antigens. Confidence Intervals were 
defined using profile-likelihood methods.
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reduced both accuracy and precision of serocatalytic model estimates of parameter tc whereas it only slightly 
affected the precision of the antibody acquisition model, illustrating the robustness of the antibody acquisition 
model.
Discussion
From 1985 to 2010, the population of Nyamisati village experienced a gradual decline of P. falciparum prevalence, 
but lack of surveillance between 1999 and 2010 hinders efforts to elucidate patterns of malaria transmission 
intensity and thereby to identify factors that have contributed to the decline32. Through mathematical model-
ling of serological data, we evaluate historical transmission patterns and confirm a reduction in P. falciparum 
transmission intensity. Serocatalytic models indicated a decrease of malaria transmission intensity but could not 
determine if the reduction pattern was more likely to be stepwise or linear. The new antibody acquisition models, 
using the complete data on antibody levels, increase both power and precision and enabled us to establish that a 
stepwise reduction in transmission decrease was most likely.
The two modelling approaches have strengths and weaknesses, which are outlined in Table 3. In high and 
moderate transmission settings, serocatalytic models are often limited by the long half-life of seropositivity and 
a plateau of very high seroprevalence reached already among young children6. This is likely to have contributed 
to the uncertainty of serocatalytic model parameter estimates in the present study. However, population anti-
body levels do not saturate as seroprevalence does, and if transmission is reduced antibody levels will drop while 
seropositivity remains high29,31,34,35. The antibody acquisition models incorporate insights from longitudinal anti-
body dynamics31 and limit the loss of information that occurs when continuous antibody data is dichotomised36, 
thereby providing additional power to detect changes in transmission intensity. The antibody acquisition models 
performed better than the corresponding serocatalytic models in this context of high to moderate transmission 
intensity. Both serocatalytic and antibody acquisition model 2 provided point-estimates of “time of change” (tc) 
that, for the majority of the antigens, clustered around 1997 to 2000. However, the antibody acquisition model 
provided more precise estimates, due to a higher power to detect changes when seroprevalence is high22,29.
Exact determination of transmission dynamics requires frequent and longitudinal sampling. However, here, 
as well as in many other settings, we are limited to cross-sectional data from single or only a few time-points. The 
presented models are plausible simplifications of the dynamics of transmission intensity in Nyamisati; nonethe-
less, they provide robust estimates of transmission intensity patterns. The 72–92% stepwise reduction of malaria 
transmission intensity, estimated by both serocatalytic and antibody acquisition models to have occurred around 
1998 to 1999, coincided with the distribution of ITNs after the cross-sectional survey in 1999. The actual ITN 
coverage after the intervention is not known, however, the distribution of 900 bed nets in a population of approxi-
mately 1500 individuals would have provided more or less universal coverage (assuming one net protects 1.8 indi-
viduals37). Although parasite prevalence in Nyamisati decreased gradually during the late 1980’s and early1990’s32, 
and although factors other than the introduction of short-lasting ITNs could have contributed to the low level of 
P. falciparum and Anopheles exposure observed in Nyamisati in 20109, our results strongly support that the single 
largest change in transmission intensity is related to the distribution of ITNs in 1999.
The lack of EIR data from the Nyamisati area is a limitation of the study. We therefore used gSG6 antibody 
responses as a proxy for vector exposure19,20. Antibody responses to gSG6 did not show any significant increase 
with age but the the age-dependent tolerance that has been shown elsewhere was not observed38. The lack of an 
age trend may be related to the short-lived nature of the response39 and limits their value in analysis using the 
present modelling approach. Nonetheless, we observe a significant reduction of both overall prevalence and levels 
of antibodies to gSG6 from 1999 to 2010 suggesting a substantial reduction of Anopheles exposure in Nyamisati.
The inclusion of antigens that have been previously evaluated in serocatalytic models15,23,27 allows us to com-
pare the value of these antigens when using antibody acquisition models. MSP-119 has been proposed suitable for 
a wide range of transmission intensities21, while the more immunogenic AMA-1 suggested for low transmission 
settings21,27. Here, antibody responses to MSP-119 and MSP-3 antigens were not particularly informative. The 
lack of age trend in antibody data for these antigens in this setting, particularly at the second cross-section is a 
major limitation for their use in both the serocatalytic and the antibody acquisition models and affects both accu-
racy and precision of model parameter estimates. For the MSP-2 proteins, antibody acquisition models, but not 
serocatalytic models, provided parameter estimates with a low level of uncertainty. A relatively low correlation 
of MSP-2_Dd2 and MSP-2_CH150/9 responses was observed and the highly polymorphic nature of the protein 
Serocatalytic models Antibody acquisition models
Strengths Strengths
•   Effective at low transmission intensities when 
seropositivity is a good indicator of exposure. •  Uses all available data.
•   Data from multiple antigens can be combined. •   Effective also at high transmission intensities where all individuals 
are seropositive.
Weaknesses Weaknesses
•   Data is compressed into a binary seronegative/
seropositive state. •  Difficult to combine data from multiple antigens.
•   Choice of seropositivity threshold is arbitrary.
•   May not be applicable if data are not log-normally distributed,  
e.g. if there are many zero measurements.
Table 3. Comparative strengths and weaknesses of the serocatalytic and antibody acquisition models.
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may pose a problem in some settings40. AMA-1 provided the most precise parameter estimates and the most 
consistent results between both the serocatalytic and antibody acquisition models. There was little saturation of 
AMA-1 antibody levels with increasing age and a high correlation between responses to the two allelic variants. 
These findings indicate the suitability of AMA-1 for a wide range of transmission settings when applying both 
serocatalytic and antibody acquisition models.
Antibody prevalence data has been used successfully to model the force of infection of malaria in different set-
tings15,21–23 as well as several other infectious diseases, e.g. dengue41,42 and trachoma43. Estimates of malaria SCR 
based on longitudinal and cross-sectional data have been shown to provide consistent results44. Here we describe 
how cross-sectional data on antibody levels can be used to model malaria transmission intensity by assuming that 
the rate at which antibody levels are acquired and decay can be used as a marker for transmission intensity. The 
method was designed for malaria but can be applied to other pathogens. We show that the use of antibody acqui-
sition models, which limits the loss of information and increases statistical power, enables sensitive detection of 
transmission changes and improves precision in estimates of malaria transmission intensity trends. We conclude 
that the new antibody acquisition models provide superior precision compared to serocatalytic models in settings 
of moderate and intense transmission where seroprevalence is high. We propose that the antibody acquisition 
models provide a new powerful tool for serological surveillance of short-, medium- and long-term trends of 
malaria transmission and highlight their potential for infectious disease surveillance.
Material and Methods
Study site and cohort. The study site, cohort and malaria prevalence in the area have been recently 
described in detail32. Briefly, the study was conducted in Nyamisati, a rural fishing village situated in the Rufiji 
river delta, Tanzania, where malaria transmission is perennial with some increase following the two rainy seasons. 
The predominant malaria vectors in the area were species belonging to the An. gambiae complex as well as An. 
funestus45. A research team monitored malaria transmission and maintained a primary health care unit from 
1985 until 2000. All malaria cases were continuously recorded through a passive case detection system 1986–88 
and 1993–99. Cross-sectional surveys were performed yearly from 1985 to 1988, from 1993 to 1999 and in 2010. 
Surveys were conducted at the start of the major rainy season and included clinical examination and collection 
of venous blood samples. There was no malariometric surveillance between 2000 and 2009. Insecticide treated 
nets (ITNs) were distributed after the surveys in 1993 (300 ITNs to pregnant women and young children) and 
in 1999 (900 ITNs). The estimated access to bed nets after the surveys, assuming average protection of 1.8 indi-
viduals per net37, was 3% in 1985, 45% in 1993–1994 and 100% in 1999. Additionally, long-lasting insecticidal 
nets were distributed after the survey in 2010. Indoor residual spraying has not been used in the area. EIR data 
has not been collected at the study site. Prevalence of P. falciparum declined gradually from 1985 to 2010 (Fig. 1). 
Prevalence by microscopy decreased from 1985 to 1999, with only minor changes in real-time PCR prevalence. A 
large reduction in parasite prevalence by PCR was observed from 1999 to 201032. To maximise the sensitivity to 
detect transmission changes, children (1–16 years of age) participating in two cross-sectional surveys conducted 
in 1999 (n = 313) and 2010 (n = 355), were included in the present study27,28. Children below 1 years of age were 
excluded due to the potential presence of maternal antibodies.
Ethical approval was obtained from the Nyamisati village board, the Ethical Review board of the National 
Institute for Medical Research in Tanzania and by the Regional Ethical Committee at Karolinska Institutet, 
Sweden (Dnr. 00–084 and 2012/1151–32). Informed consent was obtained from each participant and/or their 
guardians and experiments were carried out in accordance with approved guidelines.
Antibody assays. Detection and quantitation of IgG antibodies against P. falciparum antigens and gSG6 
were performed using a multiplex bead based immunoassay46 and ELISA19,47, respectively. The recombinant P. 
falciparum antigens included the 19 kDa fragment of merozoite surface protein 1 (MSP-119)48, two allelic forms 
of each of merozoite surface protein 2 (MSP-2) (CH150/9 and Dd2)49, merozoite surface protein 3 (MSP-3) (K1 
and 3D7)50 and apical membrane antigen 1 (AMA-1) (3D7 and FVO)51. The threshold for seropositivity was 
defined as the mean fluorescent intensity (MFI), or mean optical density (OD), plus three standard deviations 
of a negative control of pooled plasma from malaria unexposed Swedish donors. MFIs and ODs were converted 
to a relative concentration in arbitrary units (AU) using IgG standards run on each plate (see Supplementary 
Information online).
An alternative threshold for seropositivity was defined by fitting finite mixture models52,53 to the 
log-transformed antibody data distributions assuming a two-component Gaussian mixture according to a previ-
ously described method (see Supplementary Information online)23,54,55.
Antibody models. Serocatalytic models. Cross-sectional data on age-specific prevalence and levels of anti-
bodies from children 1–16 years old are assumed to represent cumulative exposure to the antigen during the 
child’s lifespan, thereby allowing us to estimate transmission patterns during the 16-year period prior to each 
cross-section. Serological data on children aged 1–16 from two cross-sections in 1999 and 2010, provide infor-
mation on transmission from 1983 to 1999 for cross-section 1, and from 1994 to 2010 for cross-section 2. Denote 
t to be the time after the start of the transmission period (in 1983), and tend the time at the end of the period (in 
2010). We use the seroconversion rate λ as a marker for transmission intensity15,21. We consider three profiles for 
changes in transmission intensity over this time period:
•  Model 1: Constant transmission
λ λ( ) = ( )t 10
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•  Model 2: Sharp drop in transmission at time tc
λ
λ
λ
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≥ ( )
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t t
t t 2
c
c c
0
•  Model 3: Linear reduction in transmission
λ λ λ λ( ) = + ( − )
( )
t t
t 3c0 end
0
If seronegative individuals become seropositive at rate λ(t), and if seropositive individuals revert at rate ρ, then 
the proportion of seropositive individuals in a cohort P is described by the differential equation
λ ρ= ( )( − ) − ( )
dP
dt
t P P1 4
This equation can be solved for the three transmission profiles to give estimates of the proportion of individuals 
of age a seropositive at each cross-section.
•  Model 1: Constant transmission
λ
λ ρ
( ) =
+
( − )
( )
λ ρ−( + )P a e1
5
a0
0
0
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where ac is the age of the child at the time of the drop in transmission (ac = a + tc − 16 for children from 
cross-section 1, and ac = a + tc − 27 for children from cross-section 2)
•  There is no analytical solution for Model 3 so it must be solved numerically
The magnitude of the reduction in seroconversion rate is defined as γ (= λc/λ0).
The serocatalytic model was fitted to age-dependent data on sero-positivity status using a binomial likeli-
hood function. The log-likelihood was maximised to obtain the maximum likelihood parameter estimate (see 
Supplementary Information online). 95% confidence intervals were calculated using the likelihood ratio test. 
Profile likelihood plots are presented in Supplementary Figure S1 online.
Antibody acquisition models. In the serocatalytic models described above all data on the continuous antibody 
levels has been reduced to a dichotomous positive or negative value. Here, we describe how the full data on 
antibody levels can be utilised. We assume that the rate at which antibody levels are acquired a can be used as 
a marker for transmission intensity31. If an individual’s antibody level is boosted at rate α(t) and decays at rate r 
then antibody levels can be described by the following differential equation
α= ( ) − ( )
dA
dt
t rA 7
We assume a (t) corresponds to the three transmission profiles outlined above.
•  Model 1: Constant transmission
α
( ) = ( − ) ( )
−A a
r
e1 8
ra0
•  Model 2: Sharp drop in transmission at time tc
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α α
α
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where ac is the age of the child at the time of the drop in transmission.
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•  Model 3: Linear reduction in transmission
α α α α α
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The magnitude of reduction in antibody acquisition rates is defined as γ ( = αc/α0).
The antibody acquisition model was fitted to age-dependent antibody level data from both cross-sections by 
assuming the geometric mean antibody level at age a is A(a) and that antibody levels are log-normally distributed 
in the cohort with standard deviation on the log scale σ. The log-likelihood was maximised to obtain the max-
imum likelihood parameter estimate (see Supplementary Information online). 95% confidence intervals were 
calculated using the likelihood ratio test. Profile likelihood plots are presented in Supplementary Figure S2 online.
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